Welcome, fellow medical investor. I'm not quite sure what your points are other than that it is indeed difficult to develop a HSV-1 vaccine. The preclinical studies on mice were and are absolutely necessary before progressing Phase 1 trials on humans. As for the 'very small' sample sizes, 20-25 subjects is standard for Phase 1 and definitely statistically significant. So I really don't know why you brought up either points. But I do agree that if there is a robust immune response in Phase II trials, Professor Frazer has won the global research race to cure HSV-1. I reckon he's got this. :)
- Forums
- ASX - By Stock
- AVR
- updated ballieu report - target range 25-55c
updated ballieu report - target range 25-55c, page-43
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.11 |
Change
-0.290(1.88%) |
Mkt cap ! $321.3M |
Open | High | Low | Value | Volume |
$15.15 | $15.39 | $15.01 | $54.11K | 3.573K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 298 | $15.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.35 | 583 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 298 | 15.110 |
1 | 500 | 15.100 |
3 | 408 | 15.000 |
1 | 1000 | 14.900 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.350 | 583 | 3 |
15.400 | 1500 | 2 |
15.500 | 372 | 1 |
15.560 | 5 | 1 |
15.660 | 1925 | 2 |
Last trade - 12.51pm 22/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online